5-MeO-MiPT

Individuals with pre-existing hypertension face elevated cardiovascular risk due to the compound's documented hypertensive and tachycardic effects.

The complex cardiovascular pattern observed in preclinical models suggests risk for individuals with pre-existing cardiac rhythm disorders.

Personal or family history of psychotic disorders is an absolute contraindication for all serotonergic psychedelics. 5-HT2A agonism may trigger or exacerbate psychotic symptoms.

Personal or family history of bipolar disorder is an absolute contraindication due to risk of psychedelic-induced mania.

Hepatic impairment may alter drug metabolism and increase exposure. The zebrafish evidence for hepatotoxicity adds concern, though human clinical relevance is uncertain.

Pregnancy and breastfeeding are absolute contraindications due to absence of safety data and the compound's potent pharmacological activity.

Concurrent MAOI use is absolutely contraindicated due to serotonin syndrome risk, a class-level concern for all serotonergic psychedelics.

Concurrent use of SSRIs or SNRIs increases serotonin syndrome risk when combined with serotonergic psychedelics.

Lithium is an absolute contraindication for serotonergic psychedelic use due to documented risk of seizures and severe adverse events.